Sarah Bennett
The Indian variant, also known as the Delta variant, is a mutation of COVID-19 that was first identified in India. It is highly contagious and has been detected in numerous countries worldwide. The effectiveness of the AstraZeneca vaccine against this variant has been a subject of interest, and studies suggest that two doses of the vaccine provide good protection. A single dose of the AstraZeneca vaccine has been found to offer lower protection against the Indian variant, and it is recommended that individuals receive both doses to achieve higher levels of immunity.
| Characteristics | Values |
|---|---|
| Protection against the Indian variant | 60% protection against the Delta variant compared to 73% for the Alpha variant |
| Number of doses required | Two doses are necessary for 60% to 80% protection against the Indian variant |
| Comparison with Pfizer vaccine | Pfizer offered better protection against the Delta variant |
| Effectiveness | The vaccine is highly effective against symptomatic disease from the Indian variant |
| Protection against hospitalisation and death | Expected to be even more effective at preventing hospitalisation and death |
| Indian variant | Also known as the Delta variant |
Explore related products
$11.67 $21.99
What You'll Learn
- Two doses of AstraZeneca are required to protect against the Indian variant
- AstraZeneca offers 97% protection against symptomatic COVID-19
- Pfizer offers better protection against the Indian variant
- AstraZeneca is effective in reducing the risk of hospitalisation
- The Indian variant is more transmissible and deadly
Two doses of AstraZeneca are required to protect against the Indian variant
The Indian variant, also known as the Delta variant, is a highly transmissible mutation of COVID-19. First identified in India, the Delta variant has now become the dominant strain of coronavirus in the UK. The variant has been associated with an increased risk of hospitalisation, estimated to be double that of the Alpha variant first identified in the UK.
The Oxford-AstraZeneca vaccine has been found to offer protection against the Delta variant. However, studies have shown that two doses are required to achieve a sufficient level of protection. A single dose of the AstraZeneca vaccine has been found to provide only 33% protection against the Indian variant, compared to 51% protection against the UK variant. In contrast, two doses of the AstraZeneca vaccine provide 60% protection against the Indian variant and 66% protection against the UK variant. This highlights the importance of receiving both doses to maximise protection against the Indian variant.
A study from India reported that the AstraZeneca vaccine offered 97% protection against COVID-19 infection. However, this study involved a relatively small number of participants, and further research is needed to confirm these findings. Nonetheless, it is clear that the AstraZeneca vaccine provides a significant level of protection against the Indian variant, particularly when both doses are administered.
It is worth noting that the Pfizer vaccine has also been found to offer protection against the Indian variant, with slightly higher efficacy rates compared to AstraZeneca. The Lancet study found that the Pfizer vaccine offered 79% protection against the Delta variant two weeks after the second dose, while AstraZeneca provided 60% protection. However, both vaccines are highly effective in reducing the risk of infection and hospitalisation due to the Delta variant.
In summary, while the AstraZeneca vaccine provides protection against the Indian variant, two doses are necessary to maximise its efficacy. It is important for individuals to receive both doses of the vaccine to ensure adequate protection against this highly transmissible variant.
Air Travel and Vaccination: What's the Connection?
You may want to see also
Explore related products
AstraZeneca offers 97% protection against symptomatic COVID-19
The AstraZeneca vaccine, also known as Covishield in India, has been found to offer 97% protection against symptomatic COVID-19. This was observed in an Indian study involving 3,235 healthcare workers who reported to Delhi's Indraprastha Apollo Hospital with symptomatic COVID-19 after receiving at least one dose of the vaccine. Of these, 85 experienced symptomatic COVID-19, with 65 being fully vaccinated and 20 partially vaccinated. Notably, only 0.06% were hospitalized, indicating a low severity of the disease among those vaccinated.
While the AstraZeneca vaccine appears effective, it is important to recognize that the Indian variant, also known as the Delta variant, has shown increased transmissibility and resistance. This variant is responsible for the vast majority of COVID-19 infections in the UK and has spread globally, causing concern among health authorities. Studies suggest that two doses of the AstraZeneca vaccine provide 60% protection against the Delta variant, compared to 73% for the Alpha variant.
It is worth noting that the effectiveness of a single dose of the AstraZeneca vaccine against the Delta variant is lower. A study by Public Health England found that a single dose provided only 33% protection against the Delta variant, emphasizing the importance of receiving both doses for optimal protection. The study also revealed that two doses of the vaccine offer much better protection, with 60% effectiveness against the Delta variant.
While the AstraZeneca vaccine may not entirely prevent infection, it significantly reduces the risk of severe disease and hospitalization. This is evident in the low hospitalization rate observed in the Indian study, where only two individuals required hospitalization, and none were admitted to intensive care or died. Furthermore, the risk of COVID-19-related hospitalization is approximately doubled in those infected with the Delta variant compared to the Alpha variant.
Overall, the AstraZeneca vaccine offers substantial protection against symptomatic COVID-19, especially when both doses are administered. However, it is important to remain vigilant as the Delta variant continues to spread and evolve, and health authorities continue to monitor vaccine effectiveness and adjust their strategies accordingly.
Parental Choice: Vaccination or Not?
You may want to see also
Explore related products
Pfizer offers better protection against the Indian variant
The Pfizer-BioNTech vaccine has been found to offer better protection against the Indian variant, also known as the Delta variant, compared to the Oxford-AstraZeneca vaccine. A study published in The Lancet journal revealed that the Pfizer vaccine offered 79 per cent protection against the Delta strain two weeks after the second dose, while AstraZeneca provided 60 per cent protection. The study, which analysed 19,543 confirmed SARS-CoV-2 infections, also found that both vaccines were effective in reducing the risk of SARS-CoV-2 infection and COVID-19 hospitalisation in individuals with the Delta variant.
While the Pfizer vaccine offers higher protection against the Indian variant, it is important to note that it still provides slightly diminished efficacy. A study by France's Pasteur Institute showed that individuals who received two doses of the Pfizer vaccine experienced a three-fold reduction in their antibodies against the Indian variant. Despite this reduction, the vaccine still offered protection. Olivier Schwartz, the institute's director and co-author of the study, confirmed that "despite slightly diminished efficacy, the Pfizer vaccine probably protects against the Indian variant."
The difference in protection levels between the Pfizer and AstraZeneca vaccines can be attributed to the antibodies produced by each vaccine. The Indian variant has developed partial resistance to antibodies, resulting in lower antibody levels in vaccinated individuals. However, even with reduced antibody levels, the Pfizer vaccine still provides a sufficient defence against the variant.
It is worth mentioning that the effectiveness of vaccines against the Indian variant may evolve as more data becomes available. Dr Mary Ramsay, Head of Immunisation at PHE, stated that "this study provides reassurance that two doses of either vaccine offer high levels of protection against symptomatic disease from the B.1.617.2 variant." She added that "we expect the vaccines to be even more effective at preventing hospitalisation and death, so it is vital to get both doses to gain maximum protection against all existing and emerging variants."
Ecuador Entry: Vaccination Requirements and Rules
You may want to see also
Explore related products
AstraZeneca is effective in reducing the risk of hospitalisation
The Delta variant, formerly known as the Indian variant, is highly contagious and has been responsible for the vast majority of COVID-19 infections in the UK. It is also more likely to cause reinfection in people who have previously had COVID-19. The variant has developed partial resistance to antibodies, which means that vaccines are less effective against it.
A single dose of the AstraZeneca vaccine provides only 33% protection against the Indian variant, compared to 51% protection against the UK variant. However, two doses of the AstraZeneca vaccine provide 60% protection against the Indian variant, and this is expected to be even higher in terms of preventing hospitalisation and death. Indeed, a study from India found that out of 3,235 healthcare workers who received at least one dose of the vaccine, only 0.06% were hospitalised.
The AstraZeneca vaccine is effective in reducing the risk of hospitalisation. A study published in The Lancet journal found that both the Oxford-AstraZeneca and Pfizer-BioNTech COVID-19 vaccines were effective in reducing the risk of SARS-CoV-2 infection and COVID-19 hospitalisation in people with the Delta VOC. The study covered the period from April 1 to June 6, 2021, and analysed 19,543 confirmed SARS-CoV-2 infections, of whom 377 were admitted to hospital for COVID-19 in Scotland.
While the AstraZeneca vaccine does provide some protection against the Indian variant, it is important to note that two doses are necessary to achieve this protection. This has been demonstrated in Bangladesh, where a single dose of the vaccine provided only 33% protection against the Indian variant, while two doses provided 60% protection. Similarly, a study in the UK found that two doses of the AstraZeneca vaccine provided 60% protection against the Delta variant, compared to 73% for the Alpha variant.
Overall, while the AstraZeneca vaccine may not be as effective against the Indian variant as it is against other variants, it still provides a significant level of protection, especially against hospitalisation and death. It is important to get both doses of the vaccine to ensure maximum protection.
Ebola Virus Vaccine: Is There Hope?
You may want to see also
Explore related products
The Indian variant is more transmissible and deadly
The SARS-CoV-2 Delta variant, first identified in India, is a highly contagious and dangerous variant of the coronavirus. It is known to double the risk of hospitalisation compared to the Alpha variant, which was initially discovered in the UK. The Indian variant has been found to have higher transmissibility and virulence, making it more deadly than its predecessor.
The Delta variant has been associated with an increased risk of hospitalisation and severe disease, particularly in individuals with five or more relevant comorbidities. This highlights the importance of vaccination and protecting those who are most vulnerable. According to a study published in The Lancet journal, the Pfizer-BioNTech and Oxford-AstraZeneca vaccines offer good protection against the Indian variant. The study analysed 19,543 confirmed SARS-CoV-2 infections, of whom 377 were admitted to hospital in Scotland.
The researchers found that the Pfizer vaccine provided 92% protection against the Alpha variant and 79% protection against the Delta variant two weeks after the second dose. On the other hand, the AstraZeneca vaccine offered 60% protection against the Delta variant and 73% for the Alpha variant. It is worth noting that two doses of either vaccine provide significantly better protection against the Delta variant than a single dose.
While the vaccines are effective in reducing the risk of infection and hospitalisation, the Indian variant has shown some resistance. Those who received the Pfizer vaccine experienced a reduction in antibodies against the Indian variant but were still protected. Similarly, individuals vaccinated with AstraZeneca showed fewer antibodies neutralising the variant. Despite this, the vaccines are still considered highly effective in preventing symptomatic disease and offering protection against hospitalisation and death.
Turkey Travel: Vaccination Requirements and Entry Rules
You may want to see also
Frequently asked questions
Yes, the Indian variant, also known as the Delta variant, is especially dangerous compared to previous mutations. It is far more transmissible than the existing dominant strain in the UK, with a reproductive number (R0) of seven, compared to the original strain's R0 of three.
A single dose of the AstraZeneca vaccine provides only 33% protection against the Indian variant. However, two doses of the AstraZeneca vaccine provide 60% protection against the Indian variant and 66% against the UK variant.
The Pfizer vaccine offered 79% protection against the Delta strain two weeks after the second dose, compared to AstraZeneca's 60% protection.
